Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as GLP-1 receptor agonists, including the popular name brands Ozempic ...
When I tell people I direct clinical research studies, I often encounter surprise. “Aren’t you a physician?” they ask. It ...
Popular drugs for diabetes and weight loss could have an unexpected side effect. Glucagon-like peptide 1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity ...
A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...
Although reports of vision problems with weight loss drugs are still rare, researchers say there is cause for concern because ...
Popular GLP-1 medications like semaglutide and tirzepatide have been linked to rare vision issues, including NAION, raising ...
HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor ... and SGLT2 inhibitors (536,068 people), as well as a control group that continued use of non-GLP-1 RA ...
The GLP-1 medication trend has taken the health and wellness world by storm, largely hailed as a game-changer for weight loss ...
They found that treatment with SGLT2 inhibitors, GLP-1 receptor agonists ... In another top story, adults with type 1 diabetes who repeatedly lose and regain body weight were more likely to ...
Opens in a new tab or window Just over half of patients with overweight or obesity discontinued their GLP-1 receptor ... Regardless of diabetes status, every 1% of body weight loss was tied ...